A Comparison of Xalatan (Latanoprost) to Apo-latanoprost and Co-latanoprost in the Treatment of Glaucoma
Status:
Unknown status
Trial end date:
2017-09-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to provide evidence that the efficacy of Xalatan will be superior
to Apo-latanoprost and Co-latanoprost in the reduction of intraocular pressure in patients
with primary open angle glaucoma. The study will also aim to prove the tolerability of
Xalatan in terms of ocular hyperemia will be equivalent to its generic counterparts.